Literature DB >> 15314679

Progress on new vaccine strategies against chronic viral infections.

Jay A Berzofsky1, Jeffrey D Ahlers, John Janik, John Morris, SangKon Oh, Masaki Terabe, Igor M Belyakov.   

Abstract

Among the most cost-effective strategies for preventing viral infections, vaccines have proven effective primarily against viruses causing acute, self-limited infections. For these it has been sufficient for the vaccine to mimic the natural virus. However, viruses causing chronic infection do not elicit an immune response sufficient to clear the infection and, as a result, vaccines for these viruses must elicit more effective responses--quantitative and qualitative--than does the natural virus. Here we examine the immunologic and virologic basis for vaccines against three such viruses, HIV, hepatitis C virus, and human papillomavirus, and review progress in clinical trials to date. We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314679      PMCID: PMC503779          DOI: 10.1172/JCI22674

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  148 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Authors:  I M Belyakov; J D Ahlers; J D Clements; W Strober; J A Berzofsky
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

3.  High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.

Authors:  M Derby; M Alexander-Miller; R Tse; J Berzofsky
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

4.  Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

Authors:  R T Schooley; C Spino; D Kuritzkes; B D Walker; F A Valentine; M S Hirsch; E Cooney; G Friedland; S Kundu; T C Merigan; M J McElrath; A Collier; S Plaeger; R Mitsuyasu; J Kahn; P Haslett; P Uherova; V deGruttola; S Chiu; B Zhang; G Jones; D Bell; N Ketter; T Twadell; D Chernoff; M Rosandich
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

5.  A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes.

Authors:  S Tourdot; A Scardino; E Saloustrou; D A Gross; S Pascolo; P Cordopatis; F A Lemonnier; K Kosmatopoulos
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

6.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Authors:  L Muderspach; S Wilczynski; L Roman; L Bade; J Felix; L A Small; W M Kast; G Fascio; V Marty; J Weber
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

7.  Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.

Authors:  J O Kahn; D W Cherng; K Mayer; H Murray; S Lagakos
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

Review 8.  Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications.

Authors:  M R Hilleman
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

9.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

10.  Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.

Authors:  Z Hel; D Venzon; M Poudyal; W P Tsai; L Giuliani; R Woodward; C Chougnet; G Shearer; J D Altman; D Watkins; N Bischofberger; A Abimiku; P Markham; J Tartaglia; G Franchini
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

View more
  41 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 2.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

3.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.

Authors:  Fraia Melchionda; Terry J Fry; Matthew J Milliron; Melissa A McKirdy; Yutaka Tagaya; Crystal L Mackall
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

4.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Authors:  Igor M Belyakov; Vladimir A Kuznetsov; Brian Kelsall; Dennis Klinman; Marcin Moniuszko; Michael Lemon; Phillip D Markham; Ranajit Pal; John D Clements; Mark G Lewis; Warren Strober; Genoveffa Franchini; Jay A Berzofsky
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

5.  Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis.

Authors:  Raghava Potula; Larisa Poluektova; Bryan Knipe; Jesse Chrastil; David Heilman; Huanyu Dou; Osamu Takikawa; David H Munn; Howard E Gendelman; Yuri Persidsky
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

Review 6.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

7.  Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects.

Authors:  C Nilsson; S Aboud; K Karlén; B Hejdeman; W Urassa; G Biberfeld
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

8.  Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?

Authors:  Mark R Schleiss
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

9.  Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.

Authors:  Soumi Gupta; Christian M Leutenegger; Gregg A Dean; Jonathan D Steckbeck; Kelly Stefano Cole; Ellen E Sparger
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.